Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
about
Dissimilar Fitness Associated with Resistance to Fluoroquinolones Influences Clonal Dynamics of Various Multiresistant BacteriaRecent advances in the understanding of antibiotic resistance in Clostridium difficile infectionAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionFourteen-genome comparison identifies DNA markers for severe-disease-associated strains of Clostridium difficileEmergence of an outbreak-associated Clostridium difficile variant with increased virulence.Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in TaiwanNAP1 strain type predicts outcomes from Clostridium difficile infection.Analysis of TcdB Proteins within the Hypervirulent Clade 2 Reveals an Impact of RhoA Glucosylation on Clostridium difficile Proinflammatory Activities.Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from a university teaching hospital in Japan.In vivo selection of moxifloxacin-resistant Clostridium difficile.Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria.Comparative genome and phenotypic analysis of three Clostridioides difficile strains isolated from a single patient provide insight into multiple infection of C. difficile.
P2860
Q26741585-E526B787-33AB-4871-B768-56F3F9DC8B24Q26767079-C5AEE521-3937-4EF2-B487-C9B4F276711AQ28084026-28CB3AD4-AB9F-4DD7-A85A-E32768361CFDQ35066741-712564A2-3D83-443A-BF37-96A2992EFF6FQ35193183-6B297166-2605-47D7-929D-B3B58E58B892Q36086377-B6E43BA5-EE0C-449D-87D0-D48A78F64B75Q36420815-7194166E-A247-4F14-8427-3DF2B1FD2DF9Q36631348-0E5B8918-53D0-4B03-8C1C-4ADB303EB19CQ39665226-A10FBAA9-6536-4792-AB23-D7FBC5567B66Q41620586-C783E4B0-7004-4AF2-B0BC-5CBF0357E8EFQ43164995-41F7DCB5-25C4-4663-BEA4-2BC5207EFC63Q46237911-BE22E05E-2C2C-4AEB-8090-DBC7696AC715Q48325945-285D4AE1-BF1C-4303-9FB1-5C1F92F2D6B4
P2860
Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Molecular characterization of ...... m difficile clinical isolates.
@en
Molecular characterization of ...... m difficile clinical isolates.
@nl
type
label
Molecular characterization of ...... m difficile clinical isolates.
@en
Molecular characterization of ...... m difficile clinical isolates.
@nl
prefLabel
Molecular characterization of ...... m difficile clinical isolates.
@en
Molecular characterization of ...... m difficile clinical isolates.
@nl
P2093
P1476
Molecular characterization of ...... m difficile clinical isolates.
@en
P2093
Andrew Simor
Andrew Walkty
David A Boyd
Denise Gravel
Dorothy Moore
Geoff Taylor
Jim Hutchinson
Kathryn Suh
Mark Miller
Michael R Mulvey
P304
P356
10.1016/J.DIAGMICROBIO.2009.12.002
P577
2010-04-01T00:00:00Z